Section of Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.
The Norwegian National Unit for Platelet Immunology, Division of Diagnostics, University Hospital of North Norway, Tromsø, Norway.
J Thromb Haemost. 2022 Mar;20(3):700-704. doi: 10.1111/jth.15604. Epub 2021 Dec 7.
Vaccine-induced immune thrombotic thrombocytopenia (VITT) has so far only been reported after adenovirus vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.
We report findings in a 25-year-old woman who presented with thrombocytopenia, venous thrombosis, elevated D-dimer levels, and high levels of platelet-activating antibodies to platelet factor 4-polyanion complexes 10 days after Gardasil 9 vaccination for human papillomavirus (HPV). The patient exhibited clinical and laboratory features in line with the recently defined VITT syndrome, described after adenoviral vector vaccination to prevent coronavirus disease 2019.
We report a case of VITT following HPV vaccination. This should raise awareness of the possibility of VITT also occurring after other vaccines, not exclusively adenoviral vector-based SARS-CoV-2 vaccines.
疫苗诱导的免疫性血栓性血小板减少症（VITT）迄今为止仅在腺病毒载体严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗接种后被报道。
我们报告了一例 25 岁女性的病例，该患者在接种 Gardasil 9 疫苗预防人乳头瘤病毒（HPV）后 10 天出现血小板减少、静脉血栓形成、D-二聚体水平升高和血小板激活抗体至血小板因子 4-聚阴离子复合物水平升高，这些抗体水平升高与最近定义的 VITT 综合征相符，该综合征描述了腺病毒载体疫苗接种预防 2019 年冠状病毒病后的 VITT 。
我们报告了一例 HPV 疫苗接种后发生的 VITT 病例。这应该引起人们对 VITT 也可能发生在其他疫苗接种后的认识，而不仅仅是腺病毒载体 SARS-CoV-2 疫苗接种后。
